New GOLD guidelines, strategies, and challenges highlighted the key developments for primary care physicians in 2019.
FDA Accepts GSK’s Submission for Use of Mepolizumab in COPD
The Prescription Drug User Fee Act date is set for May 7, 2025.
2025 GOLD Report for COPD: MeiLan Han, MD, MS, Discusses Addition of Dupilumab, Ensifentrine
The 2 newly approved COPD therapies have been added to the GOLD guidelines section on follow-up therapy, expanding clinical options for specific patient types.
New Drug Boosts COPD Lung Function, QoL Regardless of Severity: Daily Dose
Your daily dose of the clinical news you may have missed.
Single vs Multiple Inhaler Triple Therapy for COPD Could Triple Adherence, Persistence: International Data
CHEST 2024: Combined data from 4 continents found consistently better adherence/persistence when COPD triple therapy was initiated with a single inhaler.
Early Identification, Treatment of COPD Reduces Exacerbations, Health Care Burden
CHEST 2024. Initial treatment for people with COPD should begin early in the disease and leads to significantly reduced risk for exacerbations and inpatient treatment.
Ensifentrine, Novel PDE3, PDE4 Inhibitor, Improves Lung Function, QoL Regardless of COPD Severity
The combined bronchodilator/anti-inflammatory agent significantly improved lung function, symptoms and QoL in adults with moderate or severe airflow obstruction.